IPX-461, also known as bexagliflozin, is an investigational medication developed by Ionis Pharmaceuticals, Inc. in collaboration with AstraZeneca. It is a potential treatment for several rare genetic disorders, including primary hyperoxaluria type 1 (PH1), focal segmental glomerulosclerosis (FSGS), and others.
IPX-461 works by activating a specific type of receptor in the body known as the peroxisome proliferator-activated receptor alpha (PPARα). Activation of PPARα leads to the increased expression of genes involved in the breakdown of fatty acids and amino acids, which is essential for the proper functioning of peroxisomes. IPX-461
FSGS is a rare kidney disease characterized by scarring of the glomeruli, leading to kidney failure. IPX-461 has demonstrated potential in reducing proteinuria (excessive protein in the urine) and slowing disease progression in patients with FSGS. IPX-461, also known as bexagliflozin, is an investigational
The rise of antibiotic-resistant bacteria has become a pressing concern worldwide. As bacteria continue to evolve and adapt to existing antibiotics, the effectiveness of these treatments is rapidly diminishing. This has severe consequences, as patients infected with resistant bacteria often face limited treatment options, increased morbidity, and mortality. The World Health Organization (WHO) has identified antibiotic resistance as one of the biggest threats to global health, food security, and development. IPX-461 works by activating a specific type of